Andrew Cooper
Stock Analyst at Raymond James
(2.36)
# 2,425
Out of 4,842 analysts
140
Total ratings
42.74%
Success rate
-2.14%
Average return
Main Sectors:
Stocks Rated by Andrew Cooper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HAE Haemonetics | Reiterates: Strong Buy | $115 → $105 | $67.84 | +54.78% | 9 | May 9, 2025 | |
| MYGN Myriad Genetics | Reiterates: Outperform | $19 → $10 | $4.16 | +140.38% | 5 | May 7, 2025 | |
| FLGT Fulgent Genetics | Reiterates: Outperform | $24 → $25 | $20.66 | +21.01% | 2 | May 5, 2025 | |
| HOLX Hologic | Reiterates: Outperform | $90 → $71 | $62.92 | +12.84% | 12 | May 2, 2025 | |
| RVTY Revvity | Reiterates: Outperform | $145 → $120 | $91.91 | +30.56% | 8 | Apr 29, 2025 | |
| ITGR Integer Holdings | Maintains: Outperform | $145 → $150 | $119.49 | +25.53% | 2 | Apr 25, 2025 | |
| UFPT UFP Technologies | Initiates: Market Perform | n/a | $232.52 | - | 1 | Mar 28, 2025 | |
| GH Guardant Health | Reiterates: Outperform | $39 → $59 | $38.55 | +53.05% | 3 | Feb 21, 2025 | |
| AVTR Avantor | Reiterates: Outperform | $26 → $24 | $13.03 | +84.26% | 14 | Feb 10, 2025 | |
| TMO Thermo Fisher Scientific | Reiterates: Outperform | $650 → $667 | $403.75 | +65.20% | 6 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $190.47 | - | 8 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $57.62 | - | 8 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $16.54 | - | 16 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $68 → $85 | $158.05 | -46.22% | 5 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $100 → $76 | $30.75 | +147.15% | 12 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $2.59 | - | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $27.32 | - | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $7.37 | - | 14 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $26.95 | - | 8 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.84 | - | 5 | Sep 22, 2021 |
Haemonetics
May 9, 2025
Reiterates: Strong Buy
Price Target: $115 → $105
Current: $67.84
Upside: +54.78%
Myriad Genetics
May 7, 2025
Reiterates: Outperform
Price Target: $19 → $10
Current: $4.16
Upside: +140.38%
Fulgent Genetics
May 5, 2025
Reiterates: Outperform
Price Target: $24 → $25
Current: $20.66
Upside: +21.01%
Hologic
May 2, 2025
Reiterates: Outperform
Price Target: $90 → $71
Current: $62.92
Upside: +12.84%
Revvity
Apr 29, 2025
Reiterates: Outperform
Price Target: $145 → $120
Current: $91.91
Upside: +30.56%
Integer Holdings
Apr 25, 2025
Maintains: Outperform
Price Target: $145 → $150
Current: $119.49
Upside: +25.53%
UFP Technologies
Mar 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $232.52
Upside: -
Guardant Health
Feb 21, 2025
Reiterates: Outperform
Price Target: $39 → $59
Current: $38.55
Upside: +53.05%
Avantor
Feb 10, 2025
Reiterates: Outperform
Price Target: $26 → $24
Current: $13.03
Upside: +84.26%
Thermo Fisher Scientific
Feb 3, 2025
Reiterates: Outperform
Price Target: $650 → $667
Current: $403.75
Upside: +65.20%
Feb 3, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $190.47
Upside: -
Sep 26, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $57.62
Upside: -
May 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $16.54
Upside: -
Feb 20, 2024
Downgrades: Outperform
Price Target: $68 → $85
Current: $158.05
Upside: -46.22%
Feb 14, 2024
Downgrades: Outperform
Price Target: $100 → $76
Current: $30.75
Upside: +147.15%
Jul 19, 2023
Initiates: Market Perform
Price Target: n/a
Current: $2.59
Upside: -
Jul 19, 2023
Initiates: Market Perform
Price Target: n/a
Current: $27.32
Upside: -
May 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $7.37
Upside: -
Jan 18, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $26.95
Upside: -
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $2.84
Upside: -